Cytokinetics Inc (CYTK) - Total Assets
Based on the latest financial reports, Cytokinetics Inc (CYTK) holds total assets worth $1.27 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore CYTK operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Cytokinetics Inc - Total Assets Trend (2000–2025)
This chart illustrates how Cytokinetics Inc's total assets have evolved over time, based on quarterly financial data. See CYTK net asset value for net asset value and shareholders' equity analysis.
Cytokinetics Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Cytokinetics Inc's total assets of $1.27 Billion consist of 64.4% current assets and 35.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 61.9% |
| Accounts Receivable | $17.76 Million | 1.3% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how Cytokinetics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CYTK market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cytokinetics Inc's current assets represent 64.4% of total assets in 2025, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 61.9% of total assets in 2025, up from 0.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 1.3% of total assets.
Cytokinetics Inc Competitors by Total Assets
Key competitors of Cytokinetics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Genfit S.A.
PA:GNFT
|
France | €157.93 Million |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩129.10 Billion |
|
Altimmune Inc
NASDAQ:ALT
|
USA | $279.93 Million |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
Australia | AU$255.67 Million |
|
Jiangsu GDK Biotechnology Co Ltd
SHG:688670
|
China | CN¥1.48 Billion |
Cytokinetics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.21 | 5.99 | 5.90 |
| Quick Ratio | 4.21 | 5.99 | 5.90 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $640.28 Million | $796.33 Million | $302.46 Million |
Cytokinetics Inc - Advanced Valuation Insights
This section examines the relationship between Cytokinetics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 60.31 |
| Latest Market Cap to Assets Ratio | 7.25 |
| Asset Growth Rate (YoY) | 1.6% |
| Total Assets | $1.42 Billion |
| Market Capitalization | $10.33 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Cytokinetics Inc's assets at a significant premium (7.25x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Cytokinetics Inc's assets grew by 1.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Cytokinetics Inc (2000–2025)
The table below shows the annual total assets of Cytokinetics Inc from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.42 Billion | +1.63% |
| 2024-12-31 | $1.40 Billion | +70.04% |
| 2023-12-31 | $824.32 Million | -18.77% |
| 2022-12-31 | $1.01 Billion | +20.62% |
| 2021-12-31 | $841.32 Million | +57.61% |
| 2020-12-31 | $533.80 Million | +84.19% |
| 2019-12-31 | $289.81 Million | +37.24% |
| 2018-12-31 | $211.18 Million | -28.37% |
| 2017-12-31 | $294.81 Million | +73.27% |
| 2016-12-31 | $170.14 Million | +47.65% |
| 2015-12-31 | $115.24 Million | -13.33% |
| 2014-12-31 | $132.97 Million | +59.84% |
| 2013-12-31 | $83.19 Million | +7.27% |
| 2012-12-31 | $77.55 Million | +46.95% |
| 2011-12-31 | $52.77 Million | -32.34% |
| 2010-12-31 | $77.99 Million | -36.38% |
| 2009-12-31 | $122.60 Million | +40.19% |
| 2008-12-31 | $87.45 Million | -43.71% |
| 2007-12-31 | $155.37 Million | -8.34% |
| 2006-12-31 | $169.52 Million | +85.34% |
| 2005-12-31 | $91.46 Million | -28.60% |
| 2004-12-31 | $128.10 Million | +103.75% |
| 2003-12-31 | $62.87 Million | +11.94% |
| 2002-12-31 | $56.17 Million | -28.92% |
| 2001-12-31 | $79.02 Million | +29.46% |
| 2000-12-31 | $61.04 Million | -- |
About Cytokinetics Inc
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral… Read more